Home ›
NPI 1699260083
NPI deactivated
1699260083
1699260083 was paid $1.38M by Medicaid between Sep 2019 and Mar 2024, across 41 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 31% of everything it billed.
33Billing provider info1699260083
33aNPI1699260083
33bProvider type—
28Total paid$1.38M
24GClaims70,508
24DCodes billed41
24AFirst – last monthSep 2019 – Mar 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 3,327 | $44K | |
| 2020 | 10,220 | $205K | |
| 2021 | 14,333 | $245K | |
| 2022 | 17,449 | $353K | |
| 2023 | 22,331 | $436K | |
| 2024incomplete | 2,848 | $99K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 31% | 15,620 | 11,741 | $426K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 16% | 6,673 | 2,835 | $223K |
| 99205 | Prolong outpt/office vis | 11% | 2,513 | 1,930 | $154K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 9.3% | 3,285 | 2,413 | $129K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.7% | 6,111 | 4,795 | $121K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 4.4% | 1,233 | 931 | $61K |
| J9271 | Injection, pembrolizumab, 1 mg | 3.6% | 44 | 25 | $50K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3.3% | 1,119 | 863 | $46K |
| 96417 | 2.9% | 1,735 | 878 | $41K | |
| 99195 | 1.8% | 1,044 | 614 | $25K | |
| 96401 | 1.1% | 728 | 479 | $15K | |
| 96416 | 1.0% | 472 | 115 | $14K |
29 more codes
| 96411 | 1.0% | 662 | $14K | |
| 96367 | <1% | 3,928 | $10K | |
| 96415 | <1% | 960 | $9K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,014 | $8K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,472 | $7K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,110 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,051 | $5K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,126 | $5K |
| 96402 | <1% | 425 | $4K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 111 | $2K |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 516 | $2K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 642 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,419 | $872.45 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,071 | $851.33 |
| 36591 | <1% | 459 | $846.29 | |
| 99223 | Prolong inpt eval add15 m | <1% | 17 | $824.33 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 46 | $668.38 |
| J3490 | Unclassified drugs | <1% | 1,323 | $663.33 |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 16 | $199.45 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 109 | $186.82 |
| 96377 | <1% | 72 | $177.64 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 332 | $160.86 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 227 | $90.61 |
| 96368 | <1% | 260 | $48.70 | |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 27 | $47.91 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 75 | $7.22 |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 366 | $0.92 |
| S0028 | Injection, famotidine, 20 mg | 0% | 57 | $0.00 |
| 96523 | 0% | 38 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.